We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

NAMPT

NAMPT inhibitors and activators act on nicotinamide phosphoribosyltransferase in the NAD+ salvage pathway. NAMPT converts nicotinamide to nicotinamide mononucleotide, the rate-limiting step in recycling nicotinamide adenine dinucleotide (NAD+). A 2004 study showed that this salvage pathway sustains NAD+ levels and regulates sirtuin deacetylase activity in mammalian cells. FK866, described in 2003 as a noncompetitive NAMPT inhibitor, depletes NAD+ and triggers apoptosis in tumor cell lines. CHS-828, GNE-617 and STF 118804 are further inhibitors, and KPT 9274 inhibits both NAMPT and p21-activated kinase 4 (PAK4). P7C3, P7C3-A20 and SBI-797812 act in the opposite direction, and P7C3 compounds were shown in 2014 to activate NAMPT in studies of neuroprotection.

1 Item

  • JGB-1-155
    Cat. No.
    A76938
    CAS No.
    3011930-28-9

    JGB-1-155

    JGB-1-155 is a positive allosteric modulator of nicotinamide phosphoribosyltransferase (NAMPT), displaying an EC50 of 3.29 μM. This compound enhances NAD+ production, thereby mitigating oxidative stress in THP-1 human monocytes. Additionally, JGB-1-155 is effective in reducing TNFα-induced reactive oxygen species (ROS) levels in HT-22 neuronal cells, positioning it as a valuable tool for research into cellular stress responses and metabolic regulation.

    In stock View Details
    1 mg
    $235.00
    5 mg
    $590.00
    All 5 sizes

1 Item

Added to your cart

View Cart Checkout

    Loading...